Comparing Cost of Revenue Efficiency: Regeneron Pharmaceuticals, Inc. vs Geron Corporation

Biotech Giants: Regeneron vs. Geron in Cost Efficiency

__timestampGeron CorporationRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 20148901000205018000
Thursday, January 1, 20159574000392709000
Friday, January 1, 201614695000299694000
Sunday, January 1, 20178437000397061000
Monday, January 1, 201812723000434100000
Tuesday, January 1, 201951272000782200000
Wednesday, January 1, 2020500520001119900000
Friday, January 1, 20217830002437500000
Saturday, January 1, 20228680001560400000
Sunday, January 1, 20231237400001815800000
Monday, January 1, 20241970500000
Loading chart...

Unleashing the power of data

Cost of Revenue Efficiency: A Tale of Two Biotech Giants

In the competitive world of biotechnology, cost efficiency is a critical factor for success. This analysis compares the cost of revenue efficiency between Regeneron Pharmaceuticals, Inc. and Geron Corporation from 2014 to 2023. Over this period, Regeneron consistently outperformed Geron, with its cost of revenue peaking at approximately $1.8 billion in 2023, a staggering 1,370% increase from 2014. In contrast, Geron's cost of revenue showed a more volatile trend, culminating in a peak of around $123 million in 2023, a 1,284% increase from its 2014 figure. This stark contrast highlights Regeneron's robust growth and operational efficiency, while Geron faced more fluctuations. The data underscores the importance of strategic financial management in sustaining growth and competitiveness in the biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025